Andere Sprachen NewAmsterdam Pharma Company N.V. Nasdaq

Aktien

A3DUAC

NL00150012L7

NAMS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.06.2024			% 5 Tage	% 1. Jan.
19,75 ^USD	+0,41 %		+15,43 %	+76,81 %

11.06.	NewAmsterdam Pharma erhält ein weiteres US-Patent zur Verlängerung des IP-Schutzes für Obicetrapib bis Juli 2043	MT
10.06.	Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043	11.06.
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office	11.06.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	07.06.
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June	29.05.
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June	29.05.
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	21.05.
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	21.05.
NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings	21.05.
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M	09.05.
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results	09.05.
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03.05.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03.05.
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02.05.
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02.05.
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	09.04.
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	09.04.
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer	01.04.
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01.04.
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen NewAmsterdam Pharma Company N.V. Nasdaq

Aktien

A3DUAC

NL00150012L7

NAMS

Andere Sprachen

Filter